Samuel Corum/Getty Images News The Senate Committee on Health, Education, Labor, and Pensions will vote during a meeting on June 18 to subpoena Novo Nordisk ( NVO ) President Doug Langa on the high prices of its GLP-1 drugs Ozempic and Wegovy. A news release from Chairman Bernie Sanders (I-Vt) claims that the drugs, used for type 2 diabetes and weight loss, cost 10 to 15 times more in the U.S.
compared to other countries. The release also states that while Wegovy costs $1,349 a month in the U.S.
, prices in other countries are $92 in the U.K., $186 in Denmark, and $265 in Canada.
In a statement , Sanders said the committee has asked Novo Nordisk to voluntarily attend a hearing before, but has been rebuffed. The hearing when Langa could testify is scheduled for July 10. In April, the committee launched an investigation into the prices of the two medications.
More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Novo Nordisk's Ozempic cuts mortality risk in kidney disease.
